Thousands of European SMEs hold valuable process technologies, patents, and manufacturing know-how that could be commercially deployed in India's rapidly industrialising economy — yet lack the networks, legal frameworks, or market knowledge to do so. We identify Indian licensee candidates, structure non-exclusive or exclusive licensing mandates, and coordinate legal documentation — earning a percentage of the deal value on successful conclusion.
India–EU FTA Relevance
The India–EU FTA includes provisions on intellectual property protection that, if ratified, would strengthen enforcement mechanisms in India — increasing European IP holders' confidence in licensing to Indian partners. This is expected to accelerate technology transfer deals that were previously deterred by IP risk concerns.
For lump-sum technology sales, we charge 5–8% of the agreed transfer price. For royalty-based licenses, we charge 3–6% of the net present value of the projected royalty stream over the agreement term (typically calculated on a 5-year horizon). A mandate engagement fee (€2,000–5,000) is charged upfront and credited against the success commission.
All commissions confirmed in writing via NCNDA + Commission Agency Agreement before any introduction. Five-year non-circumvention protection. Payment typically net 10 business days from trigger event.
Subject-matter expertise + global network + documented deal process. The only intermediary model that works across borders.
01
Licensee Search (EU→India)
We identify Indian companies with the manufacturing capability, financial standing, and market position to effectively exploit a European technology under license — screening for technical fit and commercial motivation.
02
Licensor Search (India→EU)
Indian companies increasingly hold patented technology in pharma, software, and renewables. We identify European licensees or acquisition candidates for Indian IP holders seeking to commercialise in the EU.
03
Deal Structuring Support
We advise on lump-sum versus running royalty structures, exclusivity scope, minimum performance guarantees, sublicensing rights, and territory definitions — drawing on precedent from comparable technology licensing deals.
04
NDA, Term Sheet & LOI Coordination
We manage the process from NDA execution through term sheet negotiation to LOI signature, at which point specialist IP legal counsel takes over for the final agreement.
05
R&D and Joint Development Agreements
For technology collaborations not yet at commercialisation stage, we facilitate JDA introductions between Indian research institutions or companies and European technology firms.
Full Bilateral Scope
Everything we can facilitate
A comprehensive scope of facilitation activity within this vertical — from first introduction through to repeat order management and multi-year supply agreements.
Process technology: chemical synthesis routes, manufacturing processes
Food technology: processing innovations, functional ingredient IP
Cleantech: waste-to-energy, water treatment, renewables
Software and SaaS: B2B platforms seeking Indian market entry via licensing
Medical device technology: Class I–IIa device design IP
Bilateral Flow
India ↔ World
🇮🇳 India Provides / Sources
🌍 Global Market Provides / Seeks
European technology developers, universities, research institutes
Indian manufacturers, pharma companies, agri-business firms seeking know-how
Indian pharma/tech IP holders
European licensees, generic manufacturers, technology companies
Distribution Channel Development
We actively develop distribution channels via targeted prospecting with product samples, pilot shipments, and trial orders. Every new buyer relationship begins with a qualification call, followed by a documented sample or pilot order to prove commercial viability before any long-term commitment is made. This is the most effective route to sustainable bilateral volume.
Sector Intelligence
Historical Trends · Future Outlook · FTA Impact
Subject-matter intelligence underpinning our advisory and deal origination in this vertical. Updated annually by Vinod Kumar Jain (India-side) and Amit Jain (EU-side).
Historical Context
How This Sector Evolved
◆Technology transfer to India was long driven by joint ventures — Maruti–Suzuki, Hero–Honda, Bajaj–Kawasaki — where European and Japanese OEMs exchanged technology for market access, creating India's first generation of engineering and manufacturing competence.
◆India's Patents Act amendment (2005) brought the country into TRIPS compliance for pharmaceutical patents — creating a more predictable IP framework for European licensors considering India as a licensing destination for the first time.
◆The 2010s saw a significant shift: India moved from being primarily a technology recipient to also being a technology originator, particularly in software (NASSCOM members), pharma (generics with proprietary manufacturing routes), and space/defence.
◆European SMEs with process innovations increasingly approached Indian manufacturers — not for charity licensing but for commercial royalty income from a market too large to ignore yet too complex to enter directly without a local manufacturing partner.
◆University Technology Transfer Offices (TTOs) in Germany, Netherlands, UK, and Ireland began establishing India outreach programmes — recognising that Indian licensees could commercialise academic IP in a market their European licensees were not reaching.
Future Outlook 2025–2030
Where This Sector Is Heading
▶India–EU FTA IP chapter: if ratified with balanced provisions, will strengthen patent enforcement in India — reducing the risk premium European IP holders currently apply when contemplating Indian licensing partners.
▶Green technology transfer: EU Green Deal creating enormous demand for clean energy IP — Indian manufacturers with scale production capability seeking solar, hydrogen, and battery technology licences from European innovators.
▶AI and software licensing: Indian IT companies building proprietary AI/ML platforms seeking European software licensing partnerships; EU enterprises licensing Indian-developed AI tools with proven track records.
▶Pharma reverse transfer: Indian companies (Sun Pharma, Cipla, Biocon) now holding valuable branded formulation IP and seeking European licensees — the direction of technology transfer is increasingly bidirectional.
▶Academic collaboration: India–EU Science & Technology Agreement providing framework for joint R&D — creating pre-commercial IP developed jointly that then requires commercial licensing structuring.
🚀
India–EU FTA Impact
High Impact
The FTA's IP chapter is the most consequential provision for technology transfer facilitation. Stronger patent enforcement, clearer trade secret protection, and potential for mutual recognition of technology standards all reduce the risk premium that currently deters many European SMEs from pursuing Indian licensing. Additionally, the services chapter provisions for Mode 3 (commercial presence) will make it easier for European IP companies to establish a presence in India to manage licensing relationships directly — expanding the overall market for technology transfer advisory.
Every trade mandate carries risk. The following are the most common risks in this vertical — and exactly how Global Nexus structures deals to address each one.
⚠ Risk
IP Ownership Ambiguity in Transfer Agreement
Technology transfer agreement does not clearly define what IP is being transferred vs. licensed — seller retains rights they thought they transferred, buyer discovers limitation only post-payment.
✓ Mitigation
Technology Transfer Agreement (TTA) drafted by IP-specialised counsel on both sides. IP schedule explicitly identifies: patents (with numbers), know-how (with description), trademarks (if any), and whether transfer is exclusive/non-exclusive/limited territory.
⚠ Risk
Export Control on Dual-Use Technology
Indian technology falls under SCOMET (Special Chemicals, Organisms, Materials, Equipment and Technologies) list — export without licence is a criminal offence.
✓ Mitigation
SCOMET classification check conducted before any technology transfer mandate is accepted. DGFT export licence obtained where required (can take 3-6 months). EU import of dual-use technology also subject to EU dual-use regulation (Regulation 2021/821) — parallel EU-side compliance check.
⚠ Risk
Royalty Remittance FEMA Non-Compliance
Indian technology licensor fails to file required FEMA declaration for royalty receipts from abroad — Enforcement Directorate investigation.
✓ Mitigation
Royalty receipts structured as foreign exchange inflows under the correct FEMA purpose code. CA / tax advisor with FEMA expertise engaged before first royalty invoice is issued.
Practitioner Intelligence
Tips & Insights from the Field
Drawn from Vinod Kumar Jain's 30+ years of India-side manufacturing relationships and Amit Jain's EU-side buyer and regulatory experience. These are the insights that differentiate deals that close from those that don't.
Technology transfer mandates that begin with a full transfer (assignment of IP rights) create permanent loss of leverage for the licensor. Structure all initial arrangements as time-limited exclusive licences. Full transfer — if appropriate — only after the commercial relationship is proven over 2-3 years. The licence is the trial; the transfer is the commitment.
💡
Sub-licensing rights are the hidden value
Technology licence agreements that permit the licensee to grant sub-licences to third parties can generate royalty streams the licensor never anticipated. Restrict sub-licensing rights in the initial licence — or include sub-licensing royalty sharing (typically 50% of sub-licence revenue). Many Indian technology owners have undervalued their IP by failing to include sub-licensing provisions.
💡
India-EU FTA Technology Transfer chapter is the new framework
The India-EU FTA services chapter includes provisions facilitating technology transfer — particularly in green energy, pharma, and digital sectors. Mode 3 (commercial presence) and Mode 4 (movement of natural persons) provisions enable Indian technology companies to establish EU presence and transfer technical expertise through secondment — new pathways not available under WTO GATS.
Ready to discuss a deal in this sector?
Porto, Portugal · +91 98881 47147 Panchkula, India · +91 98881 47147
Answers drawn from twenty-plus years of bilateral trade and advisory experience across this vertical.
We do not conduct formal patent freedom-to-operate or validity analysis. We coordinate with specialist IP attorneys for this. Our role is commercial origination and deal facilitation.
Enforcement is a matter for the licensor's legal counsel under the governing law of the agreement. We recommend robust arbitration clauses and minimum royalty guarantees as structural protections.
Yes. European universities with commercialisable patents and Indian research institutions seeking technology partnerships are within our scope. We have experience coordinating TTO (Technology Transfer Office) mandates.
We help both parties converge on a commercial value range using comparable license precedents, market size analysis, and a cost-of-development proxy. Formal valuation is referred to specialist financial advisors.
Yes, with the caveat that regulatory strategy (e.g., dossier transfer, GMP knowledge transfer) requires coordination with regulatory specialists alongside our commercial facilitation.
Have a question not answered here? Write to us directly — we respond to every enquiry personally within one working day.